DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas

Cancer Research

Volumn 72, Issue 22, 2012, Pages 5867-5877

  Fukawa, Tomoya ^a   Ono, Masaya ^b   Matsuo, Taisuke ^a   Uehara, Hisanori ^a   Miki, Tsuneharu ^c   Nakamura, Yusuke ^d   Kanayama, Hiro Omi ^a   Katagiri, Toyomasa ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEAD BOX POLYPEPTIDE 31; NUCLEOPHOSMIN; PROTEIN MDM2; PROTEIN P53; REGULATOR PROTEIN; RIBOSOME RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; RNA INTERFERENCE; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; CARCINOMA, RENAL CELL; CELL NUCLEOLUS; COS CELLS; DEAD-BOX RNA HELICASES; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, RIBOSOMAL; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84869221991     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1645     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96.
2. American Cancer Society: cancer facts and figures 2010. Atlanta, GA: American Cancer Society, 2011.
3. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23:202-12.
4. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
5. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90.
6. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003;170:1141-5.
7. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received highdose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
8. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-8.
9. Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Phillip T. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 2000;6:93-8.
10. Lane BR, Rini BI, Novick AC, Campbell SC. Targeted molecular therapy for renal cell carcinoma. Urology 2007;69:3-10.
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
12. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
13. Motzer RJ, Hutson TE, Tomczak PP, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
14. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9:117-23.
15. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Euro Urol 2008;53:917-30.
16. Bellmunt J, Szczylik C, Feingold J, Strahas A, Berkenblit A. Temsirolimus safety pro file and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19:1287-392.
17. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
18. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 2006;3:115-24.
19. Petricoin EF III, Hackett JL, Lesko LJ, Puri RK, Gutman SI, Chumakov K, et al. Medical applications of microarray technologies: a regulatory science perspective. Nat Genet 2002;32:474-9.
20. Hirota E, Yan L, Tsunoda T, Ashida S, Fujime M, Shuin T, et al. Genome-wide gene expression profiles of clear cell renal cell carcinoma: Identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol 2006;29:799-827.
21. Daugeron MC, Linder P. Dbp7p, a putative ATP-dependent RNA helicase from Saccharomyces cerevisiae, is required for 60S ribosomal subunit. RNA 1998;4:566-81.
22. Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, et al. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 2007;26:6448-55.
23. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-bindingkinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 2006;66:9186-95.
24. Dobashi S, Katagiri T, Hirota E, Ashida S, Daigo Y, Shuin T, et al. Involvement of TMEM22 overexpression in the growth of renal cell carcinoma cells. Oncol Rep 2009;21:305-12.
25. Endo A, Kitamura N, Komada M. Nucleophosmin/B23 regulates ubiquitin dynamics in Nucleoli by recruiting deubiquitylating enzyme USP36. J Biol Chem 2009;284:27918-23.
26. Togashi A, Katagiri T, Ashida S, Fujioka T, Maruyama O, Wakumoto Y, et al. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res 2005;65:4817-26.
27. Murano K, Okuwaki M, Hisaoka M, Nagata K. Transcription regulation of the rRNA gene by a multifunctional nucleolar protein, B23/Nucleophosmin, through Its histone chaperone activity. Mol Cell Biol 2008;28:3114-26.
28. Ono M, Shitashige M, Honda K, Isobe T, Kuwabara H, Matsuzuki H, et al. Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics 2006;5:1338-47.
29. Frehlick LJ, Eirin-Lopez JM, Ausio J. New insights into the nucleophosmin/nucleoplasmin family of nuclear chaperones. Bioessays 2007;29:49-59.
30. Savkur RS, Olson MO. Preferential cleavage in pre-ribosomal RNA by protein B23 endoribonuclease. Nucleic Acids Res 1998;26:4508-15.
31. Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 2004;5:465-75.
32. Bernstein KA, Granneman S, Lee AV, Manickam S, Baserga SJ. Comprehensive mutational analysis of Yeast DEXD/H Box RNA helicases involved in large ribosomal subunit biogenesis. Mol Cell Biol 2006;26:1195-208.
33. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000;103:127-40.
34. Wu MH, Chang JH, Chou CC, Yung BY. Involvement of nucleophosmin/B23 in the response of HeLa cells to UV irradiation. Int J Cancer 2002;97:297-305.
35. Yao Z, Duan S, Hou D, Wang W, Wang G, Liu Y, et al. B23 acts as a nucleolar stress sensor and promotes cell survival through its dynamic interaction with hnRNPU and hnRNPA1. Oncogene 2010;29:1821-34.
36. Li J, Zhang X, Sejas DP, Bagby GC, Pang Q. Hypoxia-induced nucleophosmin protects cell death through inhibition of p53. J Biol Chem 2004;279:41275-9.
37. Li J, Sejas DP, Burma S, Chen DJ, Pang Q. Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability. Carcinogenesis 2007;28:1163-70.
38. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006;6:493-505.
39. Fumagalli S, Di Cara A, Neb-Gulati A, Natt F, Schwemberger S, Hall J, et al. al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol 2009;11:501-8.
40. Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009;16:369-77.
41. Warner JR, McIntosh KB. How common are extraribosomal functions of ribosomal proteins? Mol Cell 2009;34:3-11.
42. Burger K, Muhl B, Harasim T, Rohrmoser M, Malamoussi A, Orban M, et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem 2010;285:12416-25.
43. Borer RA, Lehner CF, Eppenberger HM, Nigg E. Major nucleolarproteins shuttle between nucleus and cytoplasm. Cell 1989;56:379-90.
44. Szebeni A, Herrera JE, Olson MO. Interaction of nucleolar protein B23 with peptides related to nuclear localization signals. Biochemistry 1995;34:8037-42.
45. Lindenboim L, Blacher E, Borner C, Stein R. Regulation of stress-induced nuclear protein redistribution: a new function of Bax and Bak uncoupled from Bcl-x(L). Cell Death Differ 2010;17:346-59.
46. Stickle NH, Cheng LS, Watson IR, Alon N, Malkin D, Irwin MS, et al. Expression of p53 in renal carcinoma cells is independent of pVHL. Mutant Res 2005:578:23-32.
47. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004;64:1951-8.